Single-agent paclitaxel in advanced non-small cell lung cancer: single-center phase II study using a 3-hour administration schedule.

2.50
Hdl Handle:
http://hdl.handle.net/10541/107637
Title:
Single-agent paclitaxel in advanced non-small cell lung cancer: single-center phase II study using a 3-hour administration schedule.
Authors:
Ranson, Malcolm R; Jayson, Gordon C ( 0000-0002-8515-8944 ) ; Perkins, S; Anderson, Heather; Thatcher, Nick
Abstract:
The efficacy and safety of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) administered as a 3-hour infusion was investigated in a phase II study involving 21 patients with stage III/IV non-small cell lung cancer. The study included two quality of life assessments (the Hospital Anxiety and Depression Scale and the Rotterdam Symptom Checklist) to test their suitability for use in a future randomized phase III trial of paclitaxel and best supportive care versus best supportive care alone. Four (19%) of the 21 patients (95% confidence interval, 8% to 38%) achieved a partial response. The median time to disease progression for all patients entered was 19 weeks. Paclitaxel was well tolerated, with dose reduction required in only one patient because of arthralgia/myalgia. No dose reductions, delays, or discontinuations were required for hematologic toxicity. Completion and compliance with quality of life questionnaires was high, and these research tools proved to be acceptable for future use in phase III studies with paclitaxel.
Affiliation:
Department of Medical Oncology, North West Lung Centre, University Hospital of South Manchester, UK.
Citation:
Single-agent paclitaxel in advanced non-small cell lung cancer: single-center phase II study using a 3-hour administration schedule. 1997, 24 (4 Suppl 12):S12-6-S12-9 Semin Oncol
Journal:
Seminars in Oncology
Issue Date:
Aug-1997
URI:
http://hdl.handle.net/10541/107637
PubMed ID:
9331111
Type:
Article
Language:
en
ISSN:
0093-7754
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorRanson, Malcolm Ren
dc.contributor.authorJayson, Gordon Cen
dc.contributor.authorPerkins, Sen
dc.contributor.authorAnderson, Heatheren
dc.contributor.authorThatcher, Nicken
dc.date.accessioned2010-07-14T14:48:29Z-
dc.date.available2010-07-14T14:48:29Z-
dc.date.issued1997-08-
dc.identifier.citationSingle-agent paclitaxel in advanced non-small cell lung cancer: single-center phase II study using a 3-hour administration schedule. 1997, 24 (4 Suppl 12):S12-6-S12-9 Semin Oncolen
dc.identifier.issn0093-7754-
dc.identifier.pmid9331111-
dc.identifier.urihttp://hdl.handle.net/10541/107637-
dc.description.abstractThe efficacy and safety of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) administered as a 3-hour infusion was investigated in a phase II study involving 21 patients with stage III/IV non-small cell lung cancer. The study included two quality of life assessments (the Hospital Anxiety and Depression Scale and the Rotterdam Symptom Checklist) to test their suitability for use in a future randomized phase III trial of paclitaxel and best supportive care versus best supportive care alone. Four (19%) of the 21 patients (95% confidence interval, 8% to 38%) achieved a partial response. The median time to disease progression for all patients entered was 19 weeks. Paclitaxel was well tolerated, with dose reduction required in only one patient because of arthralgia/myalgia. No dose reductions, delays, or discontinuations were required for hematologic toxicity. Completion and compliance with quality of life questionnaires was high, and these research tools proved to be acceptable for future use in phase III studies with paclitaxel.en
dc.language.isoenen
dc.subjectLung Canceren
dc.subjectCancer Stagingen
dc.subject.meshAdult-
dc.subject.meshAged-
dc.subject.meshAntineoplastic Agents, Phytogenic-
dc.subject.meshCarcinoma, Non-Small-Cell Lung-
dc.subject.meshDrug Administration Schedule-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshLung Neoplasms-
dc.subject.meshMale-
dc.subject.meshMiddle Aged-
dc.subject.meshNeoplasm Staging-
dc.subject.meshPaclitaxel-
dc.subject.meshQuality of Life-
dc.titleSingle-agent paclitaxel in advanced non-small cell lung cancer: single-center phase II study using a 3-hour administration schedule.en
dc.typeArticleen
dc.contributor.departmentDepartment of Medical Oncology, North West Lung Centre, University Hospital of South Manchester, UK.en
dc.identifier.journalSeminars in Oncologyen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.